Home » Topics » BioWorld Science

BioWorld Science
RSS

NeuroVia initiates phase I/II trial of NV-1205 in childhood cerebral adrenoleukodystrophy

June 11, 2018

Saniona to study Tesomet in phase IIa trial for hypothalamic obesity

June 11, 2018

First-in-human study evaluates AZD-4205 with osimertinib in advanced NSCLC

June 11, 2018

MaxCyte and NIH enter CRADA for sickle cell disease

June 11, 2018

Responses to M-7824 in phase I study lead to phase II trial in HPV-associated cancers

June 11, 2018

Tagrisso approved in E.U. for first-line EGFR-mutated NSCLC

June 11, 2018

Evgen offers interim update from phase II STEM trial of SFX-01 in advanced breast cancer

June 11, 2018

EBX-205, a new oral broad-spectrum antibiotic active against bioterrorism pathogens

June 11, 2018

Idorsia initiates phase II registration program for nemorexant in insomnia

June 11, 2018

FDA approves Venclexta plus rituximab for previously treated CLL and SLL

June 11, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 7, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...